US court orders Guardant Health to pay $245 million for cancer patent infringement

A federal judge ordered Guardant Health to pay over $245 million to TwinStrand Biosciences and the University of Washington. This judgment follows a jury verdict for infringing patented DNA sequencing technology. Guardant Health will pay an upfront amount and an ongoing royalty until March 2033. The company announced it will appeal the final judgment and is confident in its position.